Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia
PDF

Original Article

Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia

J Clin Res Pediatr Endocrinol 2026;18(1):74-84 DOI: 10.4274/jcrpe.galenos.2025.2025-7-15
, , , , , ,
PDF
Permissions

Abstract

Objective

Familial hypercholesterolemia (FH) is an inherited metabolic disorder that increases cardiovascular risk from childhood. Despite its frequency, pediatric diagnosis and treatment remain limited, particularly in developing countries.

Methods

Retrospective analysis of pediatric patients with genetically confirmed heterozygous FH (HeFH). Genetic testing included sequencing of the genes LDLR, APOB, and PCSK9. Clinical features, treatment responses, statin use, andadverse events were assessed and a comparative analysis was conducted between different statin types.

Results

Among the cohort of 124 patientsonly 28.2% of patients were diagnosed via routine lipid screening, though 90.3% had a positive family history. After diagnosis, 16.1% declined treatment and 41.1% were lost to follow-up. Most genetic diagnoses involved pathogenic LDLR variants; only a few cases involved APOB and PCSK9. Three novel LDLR variants were identified. Among treated patients, atorvastatin led to a greater median low density lipoprotein-cholesterol (LDL-C) reduction. A higher (though not statistically significant) proportion of pitavastatin users achieved LDL-C targets. LDL-C reduction was positively correlated with baseline LDL-C levels. For the majority of patients, statins were well tolerated; five patients had transient creatine kinase elevations that resolved with treatment interruption.

Conclusion

This is the first large pediatric HeFH cohort study from Türkiye and provides data on both genetic background and treatment outcome. Despite genetic confirmation, significant gaps remain in early diagnosis, treatment acceptance, and long-term follow-up. Both atorvastatin and pitavastatin proved to be safe and effective. These results suggest a need for national screening programmes, family education, dietary counselling, and consistent follow-up.

Keywords: DNA sequencing, heterozygous familial hypercholesterolemia, APOB, LDLR, PCSK9, paediatrics

Graphical Abstract

Read the full text

5 sections · 2 figures · 4 tables · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

van den Bosch SE, Hutten BA, Corpeleijn WE, Kusters DM. Familial hypercholesterolemia in children and the importance of early treatment. Curr Opin Lipidol. 2024;35:126-132. Epub 2024 Feb 14

2

Humphries SE, Futema M. Genetic determinants of the familial hypercholesterolaemia phenotype. Ann Hum Genet. 2025;89:293-304. Epub 2025 Apr 2

3

Arrobas Velilla T, Brea Á, Valdivielso P. Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: the ARIAN study. Front Genet. 2022;13:971651.

4

Rogozik J, Główczyńska R, Grabowski M. Genetic backgrounds and diagnosis of familial hypercholesterolemia. Clin Genet. 2024;105:3-12. Epub 2023 Oct 17

5

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-3490a. Epub 2013 Aug 15

6

Minhas R, Humphries SE, Qureshi N, Neil HA; NICE Guideline Development Group. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart. 2009;95:584-587; discussion 587-591. Epub 2009 Jan 23

7

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425-2437. Epub 2015 May 25

8

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-S256. Epub 2011 Nov 14

9

Banderali G, Capra ME, Biasucci G, Stracquadaino R, Viggiano C, Pederiva C. Detecting familial hypercholesterolemia in children and adolescents: potential and challenges. Ital J Pediatr. 2022;48:115.

10

Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K; Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25:751-770. Epub 2018 Jun 7

11

European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2024;403:55-66. Epub 2023 Dec 12

12

Sonmez A, Demirci I, Haymana C, Tasci I, Ayvalı MO, Ata N, Ezgu FS, Bayram F, Barcin C, Caglayan M, Ülgü MM, Birinci S, Tokgozoglu L, Satman I, Kayikcioglu M. Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: a real-life cross-sectional study from the Turkish National Database. Atherosclerosis. 2023;375:9-20. Epub 2023 May 5

13

Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, Genest J, Ray KK, Vallejo-Vaz AJ. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. circulation. 2020;141:1742-1759. Epub 2020 May 29

14

Wilson DP, Patel M. Statin use in children and adolescents - dos, don’ts and practical tips. Curr Atheroscler Rep. 2024;27:16.

15

Fiorentino R, Chiarelli F. Statins in children, an update. Int J Mol Sci. 2023;24:1366.

16

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019:CD006401.

17

Khoury M, McCrindle BW. The rationale, indications, safety, and use of statins in the pediatric population. Can J Cardiol. 2020;36:1372-1383. Epub 2020 Apr 5

18

Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547-1556.

19

Radaelli G, Sausen G, Cesa CC, Santos FS, Portal VL, Neyeloff JL, Pellanda LC. Statin treatments and dosages in children with familial hypercholesterolemia: meta-analysis. Arq Bras Cardiol. 2018;111:810-821. Epub 2018 Oct 18

20

Mamann N, Lemale J, Karsenty A, Dubern B, Girardet JP, Tounian P. Intermediate-term efficacy and tolerance of statins in children. J Pediatr. 2019;210:161-165. Epub 2019 Apr 30

21

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38-e81.

22

Wiegman A. Lipid screening, action, and follow-up in children and adolescents. Curr Cardiol Rep. 2018;20:80.

23

de Ferranti SD, Rodday AM, Parsons SK, Cull WL, O’Connor KG, Daniels SR, Leslie LK. Cholesterol screening and treatment practices and preferences: a survey of United States pediatricians. J Pediatr. 2017;185:99-105.e2. Epub 2017 Feb 13

24

Dixon DB, Kornblum AP, Steffen LM, Zhou X, Steinberger J. Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr. 2014;164:572-576. Epub 2013 Nov 16

25

EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398:1713-1725. Epub 2021 Sep 7

26

Keenan KF, Finnie RM, Simpson WG, McKee L, Dean J, Miedzybrodzka Z. Parents’ views of genetic testing and treatment of familial hypercholesterolemia in children: a qualitative study. J Community Genet. 2019;10:129-141. Epub 2018 Jun 14

27

Tsai HH, Young JL, Cherny S, Ahmed CD, Khan SS, Duquette D. “I don’t think people should die young”: perspectives of parents with children diagnosed with familial hypercholesterolemia. J Community Genet. 2024;15:549-558. Epub 2024 Aug 10

28

Kinnear FJ, Wainwright E, Perry R, Lithander FE, Bayly G, Huntley A, Cox J, Shield JP, Searle A. Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis. BMJ Open. 2019;9:e030290.

29

Motkowski R, Abramowicz P, Kubalska J, Mikołuć B, Konstantynowicz J. Efficacy and safety of statin treatment in children with familial hypercholesterolemia: outcomes of 20 years of experience. J Clin Med. 2023;12:7197.

30

Johnson PK, Mendelson MM, Baker A, Ryan HH, Warren S, Graham D, Griggs SS, Desai NK, Yellen E, Buckley L, Zachariah JP, de Ferranti SD. Statin-associated myopathy in a pediatric preventive cardiology practice. J Pediatr. 2017;185:94-98.e1. Epub 2017 Mar 29

31

Miller ML, Wright CC, Browne B. Lipid-lowering medications for children and adolescents. J Clin Lipidol. 2015;9:S67-S76. Epub 2015 Jul 2

32

Kındış E, Aygün S, Ertürk B, Kabaçam S, Lafcı NG, Tokgözoğlu L, Alikaşifoğlu M. Investigation of the genetic background of familial hypercholesterolemia in a Turkish cohort and its clinical implications. J Clin Lipidol. 2025;19:572-581. Epub 2025 Feb 21

33

Turkyilmaz A, Kurnaz E, Alavanda C, Yarali O, Kartal Baykan E, Yavuz D, Cayir A, Ata P. The spectrum of low-density lipoprotein receptor mutations in a large Turkish cohort of patients with familial hypercholesterolemia. Metab Syndr Relat Disord. 2021;19:340-346. Epub 2021 Apr 1

34

Sözen MM, Whittall R, Oner C, Tokatli A, Kalkanoğlu HS, Dursun A, Coşkun T, Oner R, Humphries SE. The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis. 2005;180:63-71.

35

Kose E, Kose M, Ozturk SI, Ozcan E, Onay H, Ozkan B. Cascade screening and treatment of children with familial hypercholesterolemia in Turkey. J Pediatr Endocrinol Metab. 2020;33:1251-1256.

36

Mollaki V, Drogari E. Genetic causes of monogenic familial hypercholesterolemia in the Greek population: lessons, mistakes, and the way forward. J Clin Lipidol. 2016;10:748-756. Epub 2016 Mar 23